Sintilimab Not Yet Recruiting Phase 4 Trials for Triple-Negative Breast Cancer Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT05843292Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer